These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 21788094)

  • 1. Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy.
    Chen HH; Yan JJ; Chen WC; Kuo MT; Lai YH; Lai WW; Liu HS; Su WC
    Lung Cancer; 2012 Feb; 75(2):228-34. PubMed ID: 21788094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.
    Yang T; Chen M; Chen T; Thakur A
    Oncol Lett; 2015 Oct; 10(4):2584-2590. PubMed ID: 26622894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinum-resistance in non-small cell lung cancer (NSCLC).
    Li ZH; Qiu MZ; Zeng ZL; Luo HY; Wu WJ; Wang F; Wang ZQ; Zhang DS; Li YH; Xu RH
    J Transl Med; 2012 Feb; 10():21. PubMed ID: 22304828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
    Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Li YQ; Zhang XY; Chen J; Yin JY; Li XP
    J Cancer Res Ther; 2018; 14(4):881-886. PubMed ID: 29970670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Expression Levels of Copper Transporter 1 and Thymidylate Synthase with Treatment Outcomes in Patients with Advanced Non-small Cell Lung Cancer Treated with S-1/Carboplatin Doublet Chemotherapy.
    Konishi M; Imai A; Fujii M; Sugimoto K; Katakami N; Imai Y; Kamoshida S
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):435-441. PubMed ID: 29479997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    Martinez-Balibrea E; Martínez-Cardús A; Musulén E; Ginés A; Manzano JL; Aranda E; Plasencia C; Neamati N; Abad A
    Int J Cancer; 2009 Jun; 124(12):2905-10. PubMed ID: 19296535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients.
    Mo H; Hao X; Liu Y; Wang L; Hu X; Xu J; Yang S; Xing P; Shi Y; Jia B; Wang Y; Li J; Wang H; Wang Z; Sun Y; Shi Y
    Cancer Med; 2016 Jun; 5(6):1116-24. PubMed ID: 26993156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.
    Cui H; Zhang AJ; McKeage MJ; Nott LM; Geraghty D; Guven N; Liu JJ
    J Inorg Biochem; 2017 Dec; 177():249-258. PubMed ID: 28551160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MAC30 is Resistant to Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Chen R; Fen Y; Lin X; Ma T; Cai H; Ding H
    Technol Cancer Res Treat; 2016 Dec; 15(6):815-820. PubMed ID: 26376695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of copper transporters in cisplatin resistance.
    Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
    Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
    Song L; Li Y; Li W; Wu S; Li Z
    J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer.
    Kim ES; Tang X; Peterson DR; Kilari D; Chow CW; Fujimoto J; Kalhor N; Swisher SG; Stewart DJ; Wistuba II; Siddik ZH
    Lung Cancer; 2014 Jul; 85(1):88-93. PubMed ID: 24792335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF13 enhances resistance to platinum drugs by regulating hCTR1 and ATP7A via a microtubule-stabilizing effect.
    Yu H; Wang H; Qie A; Wang J; Liu Y; Gu G; Yang J; Zhang H; Pan W; Tian Z; Wang C
    Cancer Sci; 2021 Nov; 112(11):4655-4668. PubMed ID: 34533854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of copper transporters in resistance to platinating agents.
    Rabik CA; Maryon EB; Kasza K; Shafer JT; Bartnik CM; Dolan ME
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):133-42. PubMed ID: 18998134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic basis for overcoming platinum resistance using copper chelating agents.
    Liang ZD; Long Y; Tsai WB; Fu S; Kurzrock R; Gagea-Iurascu M; Zhang F; Chen HH; Hennessy BT; Mills GB; Savaraj N; Kuo MT
    Mol Cancer Ther; 2012 Nov; 11(11):2483-94. PubMed ID: 22914438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D deficiency is associated with a poor prognosis in advanced non-small cell lung cancer patients treated with platinum-based first-line chemotherapy.
    Ma K; Xu W; Wang C; Li B; Su K; Li W
    Cancer Biomark; 2017; 18(3):297-303. PubMed ID: 27983538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.